HLB Life Science Co., Ltd.

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the company is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses, as well as manufactures and sells disposable syringes. Further, the company undertakes energy efficiency projects; and builds heating/heating system improvement projects, as well as renewable energy facility construction business. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co., Ltd. in December 2015. HLB Life Science Co., Ltd. was founded in 1998 and is headquartered in Hwaseong-si, South Korea.